Use of hypomethylating agents in myelodysplastic syndromes

Clinical Advances in Hematology and Oncology

Volumn 5, Issue 7, 2007, Pages 544-552

  Atallah, Ehab ^a   Garcia Manero, Guillermo ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

5 aza 2' deoxycytidine; 5 azacytidine; DNA methylation; Myelodysplastic syndromes

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; 5,6 DIHYDROAZACITIDINE; ANTINEOPLASTIC AGENT; AZACITIDINE; DNA HYPOMETHYLATING AGENT; EPIGALLOCATECHIN GALLATE; FAZARABINE; FLUCYTOSINE DEOXYRIBOSIDE; GREEN TEA EXTRACT; HISTONE DEACETYLASE INHIBITOR; HYDRALAZINE; LBH 589; MG 98; MGCD 0103; N (2 AMINOPHENYL) 4 (3 PYRIDINYLMETHOXYCARBONYLAMINOMETHYL)BENZAMIDE; NUCLEOSIDE ANALOG; POLYPHENOL; PROCAINAMIDE; RETINOIC ACID; TRICHOSTATIN A; UNCLASSIFIED DRUG; VALPROIC ACID; VORINOSTAT; ZEBULARINE;

ACUTE GRANULOCYTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CLINICAL TRIAL; CONSTIPATION; CONTINUOUS INFUSION; DNA METHYLATION; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; DRUG POTENTIATION; DRUG SAFETY; DRUG STRUCTURE; FEBRILE NEUTROPENIA; FOOD AND DRUG ADMINISTRATION; GENE DELETION; GENE EXPRESSION; GENE MUTATION; GENE REPRESSION; HUMAN; HYPERBILIRUBINEMIA; LEUKOPENIA; LOW DRUG DOSE; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; NAUSEA AND VOMITING; NEUTROPENIA; NONHUMAN; PNEUMONIA; THROMBOCYTOPENIA; TUMOR SUPPRESSOR GENE; UNITED STATES;

ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AZACITIDINE; DNA METHYLATION; DNA MODIFICATION METHYLASES; HISTONE DEACETYLASES; HUMANS; MYELODYSPLASTIC SYNDROMES; RANDOMIZED CONTROLLED TRIALS;

EID: 34848895438     PISSN: 15430790     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (78)

1. Daskalakis M, Nguyen TT, Nguyen C, et al. Demethylation of a hypermethylated P15/INK4B gene in patients with myelodysplastic syndrome by 5-Aza-2′-deoxycytidine (decitabine) treatment. Blood. 2002;100:2957-2964.
2. Jones PA, Taylor SM. Cellular differentiation, cytidine analogs and DNA methylation. Cell. 1980;20:85-93.
3. Uchida T. Kinoshita T, Nagai H, et al. Hypermethylation of the p15INK4B gene in myelodysplastic syndromes. Blood. 1997;90:1403-1409.
4. Yang AS, Doshi KD, Choi SW, et al. DNA methylation changes after 5-aza-2′-deoxycytidine therapy in patients with leukemia. Cancer Res. 2006;66: 5495-5503.
5. Glazer RI, Knode MC. 1-beta-D-arabinosyl-5-azacytosine. Cytocidal activity and effects on the synthesis and methylation of DNA in human colon carcinoma cells. Mol Pharmacol. 1984;26:381-387.
6. Cheng JC, Matsen CB, Gonzales FA, et al. Inhibition of DNA methylation and reactivation of silenced genes by zebularine. J Natl Cancer Inst. 2003;95:399-409.
7. Beaulieu N, Fournel M, MacLeod AR. Antitumor activity of MG98, an antisense oligodeoxynucleotide targeting DNA methyltransferase 1 (DNMT1) [abstract]. Clin Cancer Res. 2001;7:3800S.
8. Brueckner B, Garcia Boy R, Siedlecki P. et al. Epigenetic reactivation of tumor suppressor genes by a novel small-molecule inhibitor of human DNA methyltransferases. Cancer Res. 2005;65:6305-6311.
9. Fang MZ, Wang Y, Ai N, et al. Tea polyphenol (-)-epigallocatechin-3-gallate inhibits dna methyltransferase and reactivates methylation-silenced genes in cancer cell lines. Cancer Res. 2003;63:7563-7570.
10. Segura-Pacheco B, Trejo-Becerril C, Perez-Cardenas E, et al. Reactivation of tumor suppressor genes by die cardiovascular drugs hydralazine and procainamide and their potential use in cancer therapy. Clin Cancer Res. 2003;9:1596-1603.
11. Lee BH, Yegnasubramanian S, Lin X, Nelson WG. Procainamide is a specific inhibitor of DNA methyltransferase 1. J Biol Chem. 2005;280:40749-40756.
12. Pina IC, Gautschi JT, Wang GY, et al. Psammaplins from the sponge Pseudoceratina purpurea: inhibition of both histone deacetylase and DNA methyltransferase. J Org Chem. 2003;68:3866-3873.
13. Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med. 2003;349:2042-2054.
14. Herman JG. Hypermethylation of tumor suppressor genes in cancer. Semin Cancer Biol. 1999;9:359-367.
15. Barlow DP. Gametic imprinting in mammals. Science. 1995;270:1610-1613.
16. Goto T, Monk M. Regulation of X-chromosome iinactivation in development in mice and humans. Microbiol Mol Biol Rev. 1998;62:362-378.
17. Santini V, Kantarjian HM, Issa JP. Changes in DNA methylation in neoplasia: pathophysiology and therapeutic implications. Ann Intern Med. 2001; 134: 573-586.
18. Mund C, Hackanson B, Stresemann C, Lubbert M, Lyko F. Characterization of DNA demethylation effects induced by 5-Aza-2′-deoxycytidine in patients with myelodysplastic syndrome. Cancer Res. 2005;65:7086-7090.
19. Hellebrekers DM, Jair KW Vice E, et al. Angiostatic activity of DNA methyltransferase inhibitors. Mol Cancer Ther 2006;5:467-475.
20. Schmelz K, Wagner M, Dorken B, Tamm I. 5-Aza-2′-deoxycytidine induces p21WAF expression by demethylation of p73 leading to p53-independent apoptosis in myeloid leukemia. Int J Cancer. 2005; 114:683-695.
21. Maio M, Coral S, Fratta E, Altomonte M, Sigalotti L. Epigenetic targets for immune intervention in human malignancies. Oncogene. 2003;22:6484-6488.
22. Gollob JA, Sciambi CJ, Peterson BL et al. Phase I trial of sequential low-dose 5-aza-2′-deoxycytidine plus high-dose intravenous bolus interleukin-2 in patients with melanoma or renal cell carcinoma. Clin Cancer Res. 2006;12:4619-4627.
23. Sorm F, Piskala A, Cihak A, Vesely J. 5-Azacytidine, a new, highly effective cancerostatic. Experientia. 1964;20:202-203.
24. Pliml J, Sorm F. Synthesis of 2-deoxy-D-ribofuranosyl-5-azacytosine. Collection of Czechoslovak Chemical Communications. 1964; 29:2576-2577.
25. Sorm F, Vesely J. The activity of a new antimetabolite, 5-azacytidine, against lymphoid leukemia in AK mice. Neoplasma. 1964; 11:123-130.
26. Sorm F, Vesely J. Effect of 5-aza-2′-deoxycytidine against leukemic and hemopoietic tissues in AKR mice. Neoplasma. 1968;15:339-343.
27. Momparler RL. Pharmacology of 5-Aza-2′-deoxycytidine (decitabine). Semin Hematol. 2005;42:S9-16.
28. Momparler RL, Rossi M, Bouchard J, et al. Kinetic interaction of 5-AZA-2′-deoxycytidine-5′-monophosphate and its 5′-triphosphate with deoxycytidylate deaminase. Mol Pharmacol. 1984;25:436-440.
29. Juttermann R, Li E, Jaenisch R. Toxicity of 5-aza-2′-deoxycytidine to mammalian cells is mediated primarily by covalent trapping of DNA methyltransferase rather than DNA demethylation. Proc Natl Acad Sci USA. 1994;91: 11797-11801.
30. Taylor SM, Jones PA. Multiple new phenotypes induced in 10T1/2 and 3T3 cells treated with 5-azacytidine. Cell. 1979;17:771-779.
31. Taylor SM, Constantinides PA, Jones PA. 5-Azacytidine, DNA methylation, and differentiation. Curr Top Microbiol Immunol. 1984;108:115-127.
32. Aparicio, A, Eads CA, Leong LA, et al. Phase I trial of continuous infusion 5-aza-2′-deoxycytidine. Cancer Chemother Pharmacol. 2003;51:231-239.
33. Cashen A, Shah A, Helget A, et al. A phase I pharmacokinetic trial of decitabine administered as a 3-hour infusion to patients with acute myelogenous leukemia (AML) or myclodysplastic syndrome (MDS). ASH Annual Meeting Abstracts. 2005;106:1854.
34. Rivard GE, Momparler RL, Demers J, et al. Phase I study on 5-aza-2′-deoxycytidine in children with acute leukemia. Leuk Res. 1981;5:453-462.
35. van Groeningen CJ, Leyva A, O'Brien AM, Gail HE, Pinedo HM. Phase I and pharmacokinetic study of 5-aza-2′-deoxycytidine (NSC 127716) in cancer patients. Cancer Res. 1986;46:4831-4836.
36. Chabot GG, Bouchard J, Momparler RL. Kinetics of deamination of 5-aza-2′-deoxycytidine and cytosine arabinoside by human liver cytidine deaminase and its inhibition by 3-deazauridine, thymidine or uracil arabinoside. Biochem Pharmacol. 1983;32:1327-1328.
37. Chabot GG, Rivard GE, Momparler RL. Plasma and cerebrospinal fluid pharmacokinetics of 5-Aza-2′-deoxycytidine in rabbits and dogs. Cancer Res. 1983;43:592-597.
38. Marcucci G, Silverman L, Eller M, Lintz L, Beach CL. Bioavailability of azacitidine subcutaneous versus intravenous in patients with the myelodysplastic syndromes. J Clin Pbarmacol. 2005;45:597-602.
39. Israili ZH, Vogler WR, Mingioli ES, et al. The disposition and pharmacokinetics in humans of 5-azacytidine administered intravenously as a bolus or by continuous infusion. Cancer Res. 1976;36:1453-1461.
40. Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood. 2002; 100:2292-2302.
41. Cheson BD, Bennett JM, Kantarjian H, et al. Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood. 2000;96:3671-3674.
42. Silverman LR, McKenzie DR, Peterson BL, et al. Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B. J Clin Oncol. 2006;24: 3895-3903.
43. Silverman LR, Demakos EP, Peterson BL, et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol. 2002;20:2429-2440.
44. Silverman LR, McKenzie DR, Peterson BL, et al. Response rates using International Working Group (IWG) criteria in patients with myelodysplastic syndromes (MDS) treated with azacitidine. ASH Annual Meeting Abstracts. 2005;106:2526.
45. Kornblith AB, Herndon JE, Silverman LR, et al. Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: a Cancer and Leukemia Group B study. J Clin Oncol. 2002;20:2441-2452.
46. Silverman LR, McKenzie DR, Peterson BL, et al. Analysis of survival, AML transformation, and transfusion independence in patients with high-risk myelodysplastic syndromes (MDS) receiving azacitidine determined using a prognostic model. ASH Annual Meeting Abstracts. 2005;106:2523.
47. Silverman LR, McKenzie DR, Peterson BL, et al. Azacitidine prolongs survival and time to AML transformation in high-risk myelodysplastic syndrome (MDS) patients >= 65 years of age. ASH Annual Meeting Abstracts. 2005;106:2524.
48. Cheson BD, Bennett JM, Kopecky KJ, et al. Revised recommendations of the International Working Group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol. 2003;21:4642-4649.
49. Sudan N, Rossetti JM, Shadduck RK, et al. Treatment of acute myelogenous leukemia with outpatient azacitidine. Cancer. 2006;107:1839-1843.
50. Fabre C, Chermat F, Legros L, et al. Treatment of high risk MDS and AML post-MDS with azacytidine (AZA): preliminary results of the French ATU program. ASH Annual Meeting Abstracts. 2006;108:2664.
51. Lyons RM, Cosgriff T, Modi S, et al. Hematologic improvement, transfusion independence, and safety assessed using three alternative dosing schedules of azacitidine in patients with myelodysplastic syndromes. ASH Annual Meeting Abstracts. 2006;108:2662.
52. Rossetti JM, Falke E, Shadduck RK, et al. G-CSF Increases hematological response among patients with myelodysplasia treated with azacitidine. ASH Annual Meeting Abstracts 2006;108:4868.
53. Momparler RL, Bouffard DY, Momparler LF, et al. Pilot phase I-II study on 5-aza-2′-deoxycytidine (Decitabine) in patients with metastatic lung cancer. Anti-cancer Drugs. 1997;8:358-368.
54. Schwartsmann G, Schunemann H, Gorini CN, et al. A phase I trial of cisplatin plus decitabine, a new DNA-hypomethylating agent, in patients with advanced solid tumors and a follow-up early phase II evaluation in patients with inoperable non-small cell lung cancer. Invest New Drugs. 2000;18:83-91.
55. Zagonel V, Lo RG, Marotta G, et al. 5-Aza-2′-deoxycitidine (Decitabine) induces trilineage response in unfavourable myelodysplastic syndromes. Leukemia. 1993;7(suppl 1):30-35.
56. Issa JR Garcia-Manero G, Giles FJ, et al. Phase 1 study of low-dose prolonged exposure schedules of the hypormethytating agent 5-aza-2′-deoxycytidine (decitabine) in hematopoietic malignancies. Blood. 2004;103:1635-1640.
57. Wijermans PW, Krulder JW, Huijgens PC, Neve P. Continuous infusion of low-dose 5-Aza-2′-deoxycytidine in elderly patients with high-risk myelodysplastic syndrome. Leukemia. 1997;11(suppl 1):S19-S23.
58. Wijermans P, Lubbert M, Verhoef G, et al. Low-dose 5-aza-2′-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients. J Clin Oncol. 2000; 18:956-962.
59. Lubbert M, Wijermans P, Kunzmann R, et al. Cytogenetic responses in high-risk myelodysplastic syndrome following low-dose treatment with the DNA methylation inhibitor 5-aza-2′-deoxicytidine. Br J Haematol. 2001;114:349-357.
60. van den BJ, Lubbert M, Verhoef G, Wijermans PW. The effects of 5-aza-2′-deoxycytidine (Decitabine) on the platelet count in patients with intermediate and high-risk myelodysplastic syndromes. Leuk Res. 2004;28:785-790.
61. Kantarjian H, Issa JP, Rosenfeld CS, et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer. 2006;106:1794-1803.
62. Kantarjian H, Oki Y, Garcia-Manero G, et al. Results of a randomized study of three schedules of low-dose decitabine in higher risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood. 2007;109:52-57.
63. Ruter B, Wijermans PW, Lubbert M. Superiority of prolonged low-dose azanucleoside administration? Results of 5-aza-2′-deoxycytidine retreatment in high-risk myelodysplasia patients. Cancer. 2006;106:1744-1750.
64. Garcia-Manero G, Issa JP. Histone deacetylase inhibitors: a review of their clinical status as antineoplastic agents. Cancer Invest. 2005;23:635-642.
65. Marks PA, Richon VM, Rifkind RA. Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells. J Natl Cancer Inst. 2000;92:1210-1216.
66. Gore SD, Weng LJ, Figg WD, et al. Impact of prolonged infusions of the putative differentiating agent sodium phenylbutyrate on myelodysplastic syndromes and acute myeloid leukemia. Clin Cancer Res. 2002;8:963-970.
67. Kuendgen A, Strupp C, Aivado M, et al. Treatment of myelodysplastic syndromes with valproic acid alone or in combination with all-trans retinoic acid. Blood. 2004;104:1266-1269.
68. Pilatrino C, Cilloni D, Messa E, et al. Increase in platelet count in older, poor-risk patients with acute myeloid leukemia or myelodysplastic syndrome treated with valproic acid and all-trans retinoic acid. Cancer. 2005;104:101-109.
69. Kuendgen A, Schmid M, Knipp S, et al. Valproic acid (VPA) achieves high response rates in patients with low-risk myelodysplastic syndromes. ASH Annual Meeting Abstracts. 2005;106:789.
70. Cameron EE, Bachman KE, Myohanen S, Herman JG, Baylin SB. Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat Genet. 1999;21:103-107.
71. Yang H, Hoshino K, Sanchez-Gonzalez B, Kantarjian H, Garcia-Manero G. Antileukemia activity of the combination of 5-aza-2′-deoxcytidine with valproic acid. Leuk Res. 2005;29:739-748.
72. Garcia-Manero G, Kantarjian HM, Sanchez-Gonzalez B, et al. Phase 1/2 study of the combination of 5-aza-2′-deoxycytidine with valproic acid in patients with leukemia. Blood. 2006;108:3271-3279.
73. Soriano AO, Yang H, Tong W, et al. Significant clinical activity of the combination of 5-azacytidine, valproic acid and all-trans retinoic (ATRA) acid in leukemia: results of a phase I/II study. ASH Annual Meeting Abstracts. 2006;108:160.
74. Gore SD, Baylin S, Sugar E, et al. Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms. Cancer Res. 2006;66:6361-6369.
75. Garcia-Manero G, Yang AS, Giles F, et al. Phase I/II study of the oral isotype-selective histone deacetylase (HDAC) inhibitor MGCD0103 in combination with azacitidine in patients (pts) with high-risk myelodysplastic syndrome (MDS) or acute myelogenous leukemia (AML). ASH Annual Meeting Abstracts 2006;108:1954.
76. Garcia-Manero G, Yang H, Sanchez-Gonzalez B, et al. Final results of a phase I study of the histone deacetylase, inhibitor vorinostat (suberoyanilide hydroxamic acid, SAHA), in patients with leukemia and myelodysplastic syndrome. ASH Annual Meeting Abstracts. 2005;106:2801.
77. Gore SD, Jiemjit A, Silverman LB, et al. Combined methyltransferase/ histone deacetylase inhibition with 5-azacitidine and MS-275 in patients with MDS, CMMoL and AML: clinical response, histone acetylation and DNA damage. ASH Annual Meeting Abstracts. 2006;108:517.
78. Giles FJ, Fischer T, Cortes J, et al. A phase I/II study of intravenous LBH589, a novel histone deacetylase (HDAC) inhibitor, in patients (pts) with advanced hematologic malignancies. ASH Annual Meeting Abstracts. 2004;104:1802.